[go: up one dir, main page]

FR2882261B1 - USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES - Google Patents

USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES

Info

Publication number
FR2882261B1
FR2882261B1 FR0501861A FR0501861A FR2882261B1 FR 2882261 B1 FR2882261 B1 FR 2882261B1 FR 0501861 A FR0501861 A FR 0501861A FR 0501861 A FR0501861 A FR 0501861A FR 2882261 B1 FR2882261 B1 FR 2882261B1
Authority
FR
France
Prior art keywords
diabetes
prevention
preparation
treatment
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0501861A
Other languages
French (fr)
Other versions
FR2882261A1 (en
Inventor
Corinne Hanotin
Pierre Rosenzweig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to FR0501861A priority Critical patent/FR2882261B1/en
Priority to FR0504942A priority patent/FR2882264A1/en
Priority to FR0505228A priority patent/FR2882265B1/en
Priority to BRPI0608183-5A priority patent/BRPI0608183A2/en
Priority to CNA2006800052531A priority patent/CN101119727A/en
Priority to AU2006215444A priority patent/AU2006215444A1/en
Priority to ZA200707012A priority patent/ZA200707012B/en
Priority to MX2007009996A priority patent/MX2007009996A/en
Priority to EP06709344A priority patent/EP1853264A1/en
Priority to PCT/FR2006/000376 priority patent/WO2006087481A1/en
Priority to EA200701781A priority patent/EA011618B1/en
Priority to JP2007555669A priority patent/JP2008530189A/en
Priority to CA002597245A priority patent/CA2597245A1/en
Priority to UY29386A priority patent/UY29386A1/en
Priority to KR1020077018993A priority patent/KR20070104913A/en
Priority to TW095105631A priority patent/TW200640457A/en
Priority to ARP060100611A priority patent/AR053812A1/en
Publication of FR2882261A1 publication Critical patent/FR2882261A1/en
Priority to TNP2007000297A priority patent/TNSN07297A1/en
Priority to US11/832,865 priority patent/US20080015229A1/en
Priority to CR9293A priority patent/CR9293A/en
Priority to IL185401A priority patent/IL185401A0/en
Priority to MA30158A priority patent/MA29262B1/en
Priority to NO20074767A priority patent/NO20074767L/en
Application granted granted Critical
Publication of FR2882261B1 publication Critical patent/FR2882261B1/en
Priority to US12/402,988 priority patent/US20090197917A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0501861A 2005-02-21 2005-02-21 USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES Expired - Fee Related FR2882261B1 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
FR0501861A FR2882261B1 (en) 2005-02-21 2005-02-21 USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES
FR0504942A FR2882264A1 (en) 2005-02-21 2005-05-12 Use of rimonabant and N-peperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide, having cannabinoids receptor antagonistic activity, to treat and prevent type-II diabetes
FR0505228A FR2882265B1 (en) 2005-02-21 2005-05-23 USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES.
UY29386A UY29386A1 (en) 2005-02-21 2006-02-20 USE OF RIMONABANT FOR THE PREPARATION OF USEFUL MEDICINES IN THE PREVENTION AND TREATMENT OF TYPE2 DIABETES.
AU2006215444A AU2006215444A1 (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
ZA200707012A ZA200707012B (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
MX2007009996A MX2007009996A (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes.
EP06709344A EP1853264A1 (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
PCT/FR2006/000376 WO2006087481A1 (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
EA200701781A EA011618B1 (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
JP2007555669A JP2008530189A (en) 2005-02-21 2006-02-20 Use of rimonabant to prepare a medicament that can be used in the prevention and treatment of type 2 diabetes
CA002597245A CA2597245A1 (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
BRPI0608183-5A BRPI0608183A2 (en) 2005-02-21 2006-02-20 use of rimonabant for the preparation of drugs useful in the prevention and treatment of type 2 diabetes
KR1020077018993A KR20070104913A (en) 2005-02-21 2006-02-20 Use of Rimonabant for the manufacture of a medicament that can be used for the prevention and treatment of type 2 diabetes
TW095105631A TW200640457A (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes
CNA2006800052531A CN101119727A (en) 2005-02-21 2006-02-20 Application of rimonabant in preparing medicine for preventing and treating type 2 diabetes
ARP060100611A AR053812A1 (en) 2005-02-21 2006-02-21 USE OF RIMONABANT FOR THE PREPARATION OF USEFUL DRUGS IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES
TNP2007000297A TNSN07297A1 (en) 2005-02-21 2007-07-31 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
US11/832,865 US20080015229A1 (en) 2005-02-21 2007-08-02 Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes
CR9293A CR9293A (en) 2005-02-21 2007-08-07 USE OF RIMONABANT FOR THE PREPARATION OF USEFUL DRUGS IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES
IL185401A IL185401A0 (en) 2005-02-21 2007-08-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
MA30158A MA29262B1 (en) 2005-02-21 2007-08-23 USE OF RIMONABANT FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES
NO20074767A NO20074767L (en) 2005-02-21 2007-09-18 Use of rimonabant for the preparation of drugs that can be used in the prevention and treatment of type 2 diabetes
US12/402,988 US20090197917A1 (en) 2005-02-21 2009-03-12 Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501861A FR2882261B1 (en) 2005-02-21 2005-02-21 USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES

Publications (2)

Publication Number Publication Date
FR2882261A1 FR2882261A1 (en) 2006-08-25
FR2882261B1 true FR2882261B1 (en) 2009-02-06

Family

ID=34954874

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0501861A Expired - Fee Related FR2882261B1 (en) 2005-02-21 2005-02-21 USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES

Country Status (3)

Country Link
CN (1) CN101119727A (en)
FR (1) FR2882261B1 (en)
ZA (1) ZA200707012B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114452831B (en) * 2022-01-24 2023-04-25 中南大学湘雅医院 Surface-coated extracorporeal circulation modified membrane and preparation method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2789079B3 (en) * 1999-02-01 2001-03-02 Sanofi Synthelabo PYRAZOLECARBOXYLIC ACID DERIVATIVE, ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity

Also Published As

Publication number Publication date
CN101119727A (en) 2008-02-06
ZA200707012B (en) 2008-12-31
FR2882261A1 (en) 2006-08-25

Similar Documents

Publication Publication Date Title
EP2048153A4 (en) SUBSTITUTED SPIROCETAL DERIVATIVE AND USE THEREOF AS A MEDICAMENT IN THE TREATMENT OF DIABETES
FR20C1066I2 (en) GDF TRAPS FOR USE IN THE TREATMENT OF ANEMIA
EP1799263A4 (en) REDUCING STRESS IN THE TREATMENT OF OBESITY AND DIABETES
FR2867778B1 (en) USE OF INDAZOLECARBOXAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT AND PREVENTION OF MALARIA
FR2869541B1 (en) USE OF A COMPOSITION COMPRISING D-MANNOHEPTULOSE AND / OR PERSEITOL FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH A CHANGE IN INITIATED IMMUNITY
EP2255822A4 (en) USE OF THE EFFECTIVE SECTION OF ALKALOIDS FROM RAMULUS MORI IN THE PREPARATION OF A HYPOGLYCEMIC AGENT
EP2048152A4 (en) SPIROCETAL DERIVATIVE WITH BONDED CYCLES AND USE THEREOF AS A MEDICAMENT IN THE TREATMENT OF DIABETES
FR15C0069I2 (en) TOPICAL FORMULATION OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS
EP1957077A4 (en) SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
EP2139475A4 (en) USE OF PDE7 INHIBITORS IN THE TREATMENT OF
EP1817003A4 (en) POROUS PHOTONIC CRYSTALS FOR THE OCULAR ADMINISTRATION OF DRUGS
FR15C0030I2 (en) 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS AND USE THEREOF IN THE SUPPRESSION AND TREATMENT OF DISEASES
FR2854074B1 (en) USE OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS
EP1965823A4 (en) METHODS OF ADMINISTERING HYPOGLYCEMIC AGENTS
EP2185202A4 (en) USE OF INTERLEUKIN-22 IN THE TREATMENT OF HEPATIC STEATOSIS
EP2207557A4 (en) USE OF METALLIC ASTRINGENTS FOR THE TREATMENT AND PREVENTION OF HEAVY-LEAF KNEES
EP2036566A4 (en) USE OF 20 (S) -PROTOPANOXADIOL IN THE MANUFACTURE OF ANTIDEPRESSANTS
EP2047853A4 (en) USE OF MARINE STEROID IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF NEURONAL INJURIES
EP2255816A4 (en) USE OF COMPOUNDS EXTRACTED FROM MOMORDICA CHARANTIA L. IN THE MANUFACTURE OF MEDICAMENTS FOR THE PREVENTION AND TREATMENT OF DIABETES AND OBESITY
MA28844B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND ETHYNYLTRADIOL
EP1679070A4 (en) USE OF L-BUTYLPHTALIDE IN THE MANUFACTURE OF MEDICAMENTS FOR THE PREVENTION AND TREATMENT OF CEREBRAL INFARCTION
FR2919187B1 (en) USE OF YEAST SKIN FOR THE TREATMENT AND / OR PREVENTION OF HYPERINSULINEMIA.
FR2882261B1 (en) USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES
EP1889618A4 (en) COMBINED MEDICATION FOR THE TREATMENT OF DIABETES
FR2882265B1 (en) USE OF A PYRAZOLE DERIVATIVE FOR THE PREPARATION OF MEDICAMENTS USEFUL IN THE PREVENTION AND TREATMENT OF TYPE 2 DIABETES.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20101029